Technology
Neonode transitions to automotive production amid rising operating costs
Neonode (NASDAQ:NEON) reported first-quarter revenue from continuing operations of $0.6 million, a 19.7% increase compared to the same period in 2025.
United States Últimas notícias
Todas as matérias desta categoria, das mais recentes às mais antigas.
Transport and logistics
FedEx board finalizes spin-off of freight business set for June 1
FedEx (NYSE:FDX) announced that it will execute the separation of its freight business through a tax-free, pro rata dividend of 80.1% of the outstanding shares of the newly formed FedEx Freight Holding Company.
-640x359.webp&w=3840&q=75)
Compass Pathways swings to Q1 profit on warrant gains and massive cash influx
Compass Pathways (NASDAQ:CMPS) reported first-quarter net income of $91.2 million, or $0.71 per basic share, a dramatic reversal from the $17.9 million loss recorded in the same period last year.
Health
DarioHealth narrows loss as digital platform pivots to high-margin recurrent revenue
DarioHealth (NASDAQ:DRIO) posted first-quarter revenue of $5.6 million, a 6.7% increase from the fourth quarter of 2025.
Technology
Nebius Group surges as AI cloud revenue smashes forecasts
Nebius Group (NASDAQ:NBIS) reported a first-quarter profit of $621.2 million, or $2.11 per share.
Technology
CTW reports improved segment profits amid 1H 2026 international expansion
CTW (NASDAQ:CTW) announced Wednesday that revenue for the six months ending January 31, 2026, reached $40.9 million, a 1% decline from the $41.2 million reported in the prior-year period.
Oil and Gas
Costamare Bulkers reports rising profits and liquidity on active fleet renewal
Costamare Bulkers (NYSE:CMDB) reported first-quarter net income of $9.9 million, or $0.41 per share.
Technology
Valens Semiconductor tops Q1 estimates as gross margins surpass guidance
Valens Semiconductor (NYSE:VLN) posted first-quarter revenue of $16.9 million, edging past its guidance range of $16.3 million to $16.7 million.
Pfizer’s Hympavzi gains EU approval for hard-to-treat hemophilia patients
Pfizer (NYSE:PFE) announced Wednesday that European regulators have cleared Hympavzi for adolescents and adults with hemophilia A or B with inhibitors, marking a significant expansion for the non-factor therapy in the 27 EU member states, Iceland, Liechtenstein, and Norway.
Health
Arbutus Biopharma swings to $169.7M net income in Q1 2026
Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on infectious diseases, reported its financial results for the first quarter ended March 31, 2026.
Health
BrainsWay net income doubles as Deep TMS shipments hit all-time high
BrainsWay (NASDAQ:BWAY) delivered a powerful first-quarter 2026 performance, marked by a 35% year-over-year revenue increase to $15.5 million.
Altimmune ends Q1 with $332M cash, secures FDA breakthrough therapy designation for Pemvidutide in MASH
Altimmune (NASDAQ:ALT), a clinical-stage biopharmaceutical company developing treatments for metabolic and liver diseases, reported its first-quarter 2026 financial results and provided a business update.